Pulse Biosciences to Present Late-Breaking Findings from First-in-Human Feasibility Study of nPulse™ Cardiac Surgical System at 39th Annual Meeting of the European Association for Cardio-Thoracic Surgery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2025
0mins
Should l Buy PLSE?
Source: Newsfilter
Successful Treatment of Atrial Fibrillation: Pulse Biosciences announced positive results from a feasibility study of its nPulse™ Cardiac Surgical System, successfully treating 30 patients with atrial fibrillation using its novel nanosecond pulsed field ablation technology.
High Efficacy and Safety: The study reported a 94% success rate in pulmonary vein isolation at three months, with no severe adverse events or nerve damage, highlighting the system's rapid and effective ablation capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 23.400
Low
22.00
Averages
22.00
High
22.00
Current: 23.400
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences Shares Surge on Positive nPulse Catheter Study Results
- Promising Clinical Data: Pulse Biosciences presented significant clinical data for its nPulse Cardiac Catheter at the Annual AF Symposium in Boston, demonstrating successful treatment outcomes for atrial fibrillation in 150 patients, showcasing rapid procedure times and minimal adverse effects, potentially positioning nPulse as a market leader.
- Stock Price Surge: PLSE shares rose 4.05% to $21.59 in premarket trading on Monday, trading 49% above its 20-day simple moving average, indicating strong short-term momentum, despite a 7.20% decline over the past 12 months.
- Technical Indicator Analysis: The current RSI stands at 75.62, indicating the stock is in overbought territory, while the MACD is above its signal line, reflecting bullish momentum; however, investors should exercise caution due to potential overextension.
- Market Performance Assessment: According to Benzinga Edge, Pulse Biosciences' stock scored 68.22 in momentum, indicating strong performance relative to the broader market, yet investors should remain vigilant given the overbought RSI condition and monitor for any signs of reversal.
See More
Pulse Biosciences Unveils Key Clinical Data for nPulse Catheter
- Clinical Data Release: Pulse Biosciences presented clinical data for its nPulse cardiac catheter at the 2026 AF Symposium, successfully treating 150 patients with atrial fibrillation, showcasing rapid procedure times and minimal adverse effects, highlighting the technology's potential in atrial fibrillation treatment.
- Study Results Validation: The results from a study of 165 patients validated the safety and efficacy of the nPulse catheter system, with CEO Paul LaViolette noting its clear advantages in lesion quality and speed, potentially establishing it as a first-in-class system.
- Optimistic Treatment Outlook: The data suggest that the nPulse catheter could reduce atrial fibrillation recurrence rates, typically ranging from 20-25%, as Pulse Biosciences prepares to treat additional patients in the U.S. and Europe, initiating a pivotal IDE study.
- Strong Stock Performance: Pulse Biosciences saw trading volume surge to 1.68 million shares, significantly above the average of 183,000 shares, with the stock price rising 38.02% to $14.95, indicating a strong bullish setup and potential breakout above the $20 resistance level.
See More
U.S. Stocks Rise as Dow Jones Gains Over 700 Points
- Dow Jones Performance: The Dow Jones index rose over 700 points on Friday, indicating a strong market rebound that reflects investor optimism about economic recovery, which could further drive consumer spending and investment.
- Strategic Shares Surge: Strategy shares jumped 14.1% to $122.56 on Friday, signaling a positive market outlook for the company and potentially attracting more investor interest in its future growth prospects.
- Overall Market Trend: The overall rise in U.S. stocks suggests a restoration of investor confidence, which may lead to increased capital inflows into the stock market, thereby promoting economic growth and corporate earnings.
- Market Data Source: This market update is provided by Benzinga APIs, highlighting improved market information transparency that aids investors in making more informed decisions.
See More
Pulse Biosciences Reveals Clinical Data on nPulse Cardiac Catheter
- Clinical Study Results: Pulse Biosciences successfully treated 150 patients with atrial fibrillation in its first-in-human feasibility study of the nPulse cardiac catheter, demonstrating rapid procedure times and minimal adverse effects, indicating significant potential for this technology in cardiac treatment.
- Safety and Efficacy: The findings reveal a strong safety profile and durable pulmonary vein isolation at 6 and 12 months, exceeding expectations for atrial fibrillation treatment and suggesting a potential shift in treatment standards within the field.
- International Collaboration: A total of 165 patients have been treated under the guidance of nine investigators across Europe, showcasing the technology's potential for international application and furthering Pulse Biosciences' expansion in the global market.
- Future Development Plans: The company aims to initiate pivotal IDE studies in the U.S. and Europe, intending to revolutionize atrial fibrillation treatment through nanosecond pulsed field ablation technology, ultimately enhancing patient quality of life.
See More
Pulse Biosciences Achieves Success in Cardiac Catheter Study
- Clinical Success Rate: The nPulse cardiac catheter achieved a 100% procedural success rate at 6 months and 96% at 12 months among 150 patients, demonstrating the technology's effectiveness and durability in treating atrial fibrillation.
- Efficiency Improvement: The average number of applications per procedure was 16.1, with total procedure times averaging 65 minutes and fluoroscopy times at 9.8 minutes, indicating significant efficiency gains over traditional methods.
- Strong Safety Profile: Only 1.3% of the 150 subjects experienced serious adverse events related to the primary safety endpoint, underscoring the system's safety and enhancing confidence in its clinical application.
- Broad Market Potential: The Chief Medical Officer of Pulse Biosciences noted that the nPulse technology has the potential to revolutionize atrial fibrillation treatment, with plans to expand patient treatment in Europe and the U.S., thereby increasing market adoption.
See More
Pulse Biosciences to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Participation: Pulse Biosciences is scheduled to present on January 14, 2026, at the J.P. Morgan Healthcare Conference in San Francisco, showcasing its innovative nPulse™ technology, which is expected to attract attention from investors and the healthcare industry, thereby enhancing the company's visibility in the bioelectric medicine sector.
- Technology Introduction: The company leverages its proprietary Nanosecond Pulsed Field Ablation (nsPFA™) technology to non-thermally clear cells while sparing adjacent noncellular tissue, demonstrating its potential in treating atrial fibrillation and possibly improving patients' quality of life significantly.
- Market Prospects: Pulse Biosciences is actively pursuing the development of its nPulse technology for use in atrial fibrillation and other markets, which, if successful, could lead to substantial health improvements for both healthcare providers and patients, further driving the company's strategic growth in medical innovation.
- Investor Relations: The company will provide a live and recorded webcast of the presentation on its investor website, enhancing interaction with investors and increasing transparency, which may attract more investor interest and trust.
See More
Pulse Biosciences Shares Surge on Positive nPulse Catheter Study Results
- Promising Clinical Data: Pulse Biosciences presented significant clinical data for its nPulse Cardiac Catheter at the Annual AF Symposium in Boston, demonstrating successful treatment outcomes for atrial fibrillation in 150 patients, showcasing rapid procedure times and minimal adverse effects, potentially positioning nPulse as a market leader.
- Stock Price Surge: PLSE shares rose 4.05% to $21.59 in premarket trading on Monday, trading 49% above its 20-day simple moving average, indicating strong short-term momentum, despite a 7.20% decline over the past 12 months.
- Technical Indicator Analysis: The current RSI stands at 75.62, indicating the stock is in overbought territory, while the MACD is above its signal line, reflecting bullish momentum; however, investors should exercise caution due to potential overextension.
- Market Performance Assessment: According to Benzinga Edge, Pulse Biosciences' stock scored 68.22 in momentum, indicating strong performance relative to the broader market, yet investors should remain vigilant given the overbought RSI condition and monitor for any signs of reversal.
See More
Pulse Biosciences Unveils Key Clinical Data for nPulse Catheter
- Clinical Data Release: Pulse Biosciences presented clinical data for its nPulse cardiac catheter at the 2026 AF Symposium, successfully treating 150 patients with atrial fibrillation, showcasing rapid procedure times and minimal adverse effects, highlighting the technology's potential in atrial fibrillation treatment.
- Study Results Validation: The results from a study of 165 patients validated the safety and efficacy of the nPulse catheter system, with CEO Paul LaViolette noting its clear advantages in lesion quality and speed, potentially establishing it as a first-in-class system.
- Optimistic Treatment Outlook: The data suggest that the nPulse catheter could reduce atrial fibrillation recurrence rates, typically ranging from 20-25%, as Pulse Biosciences prepares to treat additional patients in the U.S. and Europe, initiating a pivotal IDE study.
- Strong Stock Performance: Pulse Biosciences saw trading volume surge to 1.68 million shares, significantly above the average of 183,000 shares, with the stock price rising 38.02% to $14.95, indicating a strong bullish setup and potential breakout above the $20 resistance level.
See More
U.S. Stocks Rise as Dow Jones Gains Over 700 Points
- Dow Jones Performance: The Dow Jones index rose over 700 points on Friday, indicating a strong market rebound that reflects investor optimism about economic recovery, which could further drive consumer spending and investment.
- Strategic Shares Surge: Strategy shares jumped 14.1% to $122.56 on Friday, signaling a positive market outlook for the company and potentially attracting more investor interest in its future growth prospects.
- Overall Market Trend: The overall rise in U.S. stocks suggests a restoration of investor confidence, which may lead to increased capital inflows into the stock market, thereby promoting economic growth and corporate earnings.
- Market Data Source: This market update is provided by Benzinga APIs, highlighting improved market information transparency that aids investors in making more informed decisions.
See More
Pulse Biosciences Reveals Clinical Data on nPulse Cardiac Catheter
- Clinical Study Results: Pulse Biosciences successfully treated 150 patients with atrial fibrillation in its first-in-human feasibility study of the nPulse cardiac catheter, demonstrating rapid procedure times and minimal adverse effects, indicating significant potential for this technology in cardiac treatment.
- Safety and Efficacy: The findings reveal a strong safety profile and durable pulmonary vein isolation at 6 and 12 months, exceeding expectations for atrial fibrillation treatment and suggesting a potential shift in treatment standards within the field.
- International Collaboration: A total of 165 patients have been treated under the guidance of nine investigators across Europe, showcasing the technology's potential for international application and furthering Pulse Biosciences' expansion in the global market.
- Future Development Plans: The company aims to initiate pivotal IDE studies in the U.S. and Europe, intending to revolutionize atrial fibrillation treatment through nanosecond pulsed field ablation technology, ultimately enhancing patient quality of life.
See More
Pulse Biosciences Achieves Success in Cardiac Catheter Study
- Clinical Success Rate: The nPulse cardiac catheter achieved a 100% procedural success rate at 6 months and 96% at 12 months among 150 patients, demonstrating the technology's effectiveness and durability in treating atrial fibrillation.
- Efficiency Improvement: The average number of applications per procedure was 16.1, with total procedure times averaging 65 minutes and fluoroscopy times at 9.8 minutes, indicating significant efficiency gains over traditional methods.
- Strong Safety Profile: Only 1.3% of the 150 subjects experienced serious adverse events related to the primary safety endpoint, underscoring the system's safety and enhancing confidence in its clinical application.
- Broad Market Potential: The Chief Medical Officer of Pulse Biosciences noted that the nPulse technology has the potential to revolutionize atrial fibrillation treatment, with plans to expand patient treatment in Europe and the U.S., thereby increasing market adoption.
See More
Pulse Biosciences to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Participation: Pulse Biosciences is scheduled to present on January 14, 2026, at the J.P. Morgan Healthcare Conference in San Francisco, showcasing its innovative nPulse™ technology, which is expected to attract attention from investors and the healthcare industry, thereby enhancing the company's visibility in the bioelectric medicine sector.
- Technology Introduction: The company leverages its proprietary Nanosecond Pulsed Field Ablation (nsPFA™) technology to non-thermally clear cells while sparing adjacent noncellular tissue, demonstrating its potential in treating atrial fibrillation and possibly improving patients' quality of life significantly.
- Market Prospects: Pulse Biosciences is actively pursuing the development of its nPulse technology for use in atrial fibrillation and other markets, which, if successful, could lead to substantial health improvements for both healthcare providers and patients, further driving the company's strategic growth in medical innovation.
- Investor Relations: The company will provide a live and recorded webcast of the presentation on its investor website, enhancing interaction with investors and increasing transparency, which may attract more investor interest and trust.
See More
